Melatonin in vivo prolongs cardiac allograft survival in rats

Journal of Pineal Research
Florian J JungStephan Korom

Abstract

Melatonin, secreted by the pineal gland, is a multifunctional agent which (i) protects tissues from damage through free radical scavenging and attenuates ischemia/reperfusion injury in organ grafts; (ii) acts synergistically with cellular antioxidants; and (iii) displays complex, dose-dependent immunoenhancing and suppressing effects in vitro and in vivo. We analyzed the immunomodulatory effect of melatonin on acute allograft rejection. Cardiac grafts were transplanted from LBNF1 to LEW rats and anastomosed to the abdominal great vessels. The effect of low-dose (LD; 20 mg/kg/day) and high-dose (HD; 200 mg/kg/day) melatonin treatment in recipients compared with untreated controls was investigated. HD melatonin therapy abrogated acute rejection, significantly prolonging allograft survival (mean survival: 12.3 +/- 1 days S.D., n = 8, P < 0.0001) compared with untreated controls, which rapidly reject the transplant (6.3 +/- 1 days n = 12). LD therapy did not extend survival significantly (7.3 +/- 1.1 days, n = 12). Allospecific IgM showed a significant decrease in animals receiving HD therapy versus untreated recipients at days 10 and 14 post-transplantation (P < 0.01), whereas in the LD group at day 10, a significant increase in a...Continue Reading

Citations

Aug 4, 2006·Clinical Pharmacokinetics·Massimo Baraldo, Mario Furlanut
Feb 19, 2010·Expert Opinion on Pharmacotherapy·Mohamed Amine ZaoualiJoan Roselló-Catafau
Aug 11, 2015·Molecular Nutrition & Food Research·Dres DamgaardClaus Henrik Nielsen
Aug 28, 2009·Journal of Pineal Research·Gu-Jiun LinHuey-Kang Sytwu
Mar 15, 2008·Journal of Pineal Research·Markus CardellStephan Korom
Nov 30, 2005·Journal of Pineal Research·Irina SukhotinaAlexander Lerchl
Nov 1, 2011·American Journal of Reproductive Immunology : AJRI·Masoud HemadiAli Khodadai
Jul 2, 2011·Journal of Pineal Research·Francisco A García-GilJoaquín J García
May 31, 2011·Transplantation Proceedings·R CaliaS Agnes
Jun 12, 2016·Journal of Ovarian Research·M E ShiromaJ M Soares
Apr 14, 2016·The Journal of Endocrinology·Eduardo Esteban-ZuberoRussel J Reiter
Apr 24, 2013·International Journal of Molecular Sciences·Antonio Carrillo-VicoJuan M Guerrero
Jun 4, 2013·International Journal of Molecular Sciences·Gu-Jiun LinHuey-Kang Sytwu
Sep 24, 2020·International Urology and Nephrology·Houssem MarzouguiHend Hachicha
Jun 11, 2020·Revista da Associação Médica Brasileira·Carolina F HaddadJosé Maria Soares Júnior
Nov 11, 2018·International Journal of Molecular Sciences·Philipp StieglerPeter Schemmer
Aug 29, 2020·European Journal of Pharmacology·Puneet Kaur Randhawa, Manish Kumar Gupta
Aug 28, 2021·International Journal of Molecular Sciences·Viktorija ZitkutePeter Schemmer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.